Provisional Treatment of Volumetric Muscle Loss With Insulin-like Growth Factor 1 Releasing Muscle Void Fillers.

Clark AR, Adams AT, McKinley TO, Natoli RM, Dearth CL, Goldman SM

The Journal of surgical research18 Dec 2025

PMID41418663DOI10.1016/j.jss.2025.11.043PepBankPUB-41418663

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with volumetric muscle loss, high-dose PLGA-encapsulated IGF1-LR3 increased muscle weight compared with control at 28 d after implantation.
In plain wordsIn rats with muscle loss, a high dose of IGF1-LR3 in a hydrogel raised muscle weight compared with control.
Peptide
IGF-1 LR3
Outcome
IncreaseMuscle weight at 28 d
Study
ratn: not reported in source
volumetric muscle loss
Comparator
Control (no IGF1-LR3)
Outcome group
Muscle injury and repair · Musculoskeletal
Studied dose
280 ug PLGA-encapsulated · implanted in hydrogel muscle void filler · 28 daysAs given in this study (rat).
Source sentences
Summary
High-dose PLGA-encapsulated IGF1-LR3 resulted in increased muscle weight compared to the control group at 28 d post implantation.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult male Lewis rats underwent VML surgery, followed by implantation of a polyethylene glycol-acrylate MVF containing either soluble or poly(lactic-co-glycolic acid) (PLGA)-encapsulated IGF1-LR3 at a low (28 μg) or high (280 μg) dose, or no IGF1-LR3 (control).
Report a problemFND-4141866301
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with volumetric muscle loss, IGF1-LR3 groups did not differ from each other or control in specific torque.
In plain wordsIn rats with muscle loss, IGF1-LR3 did not change muscle strength relative to muscle size.
Peptide
IGF-1 LR3
Outcome
No significant changeSpecific torque
Study
ratn: not reported in source
volumetric muscle loss
Comparator
Control (no IGF1-LR3)
Outcome group
Muscle injury and repair · Musculoskeletal
Studied dose
28 ug or 280 ug · implanted in hydrogel muscle void fillerAs given in this study (rat).
Source sentences
Summary
However, no differences were observed in specific torque or maximum torque production between any experimental groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult male Lewis rats underwent VML surgery, followed by implantation of a polyethylene glycol-acrylate MVF containing either soluble or poly(lactic-co-glycolic acid) (PLGA)-encapsulated IGF1-LR3 at a low (28 μg) or high (280 μg) dose, or no IGF1-LR3 (control).
Report a problemFND-4141866302
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with volumetric muscle loss, IGF1-LR3 groups did not differ from each other or control in maximum torque production.
In plain wordsIn rats with muscle loss, IGF1-LR3 did not change maximum muscle force.
Peptide
IGF-1 LR3
Outcome
No significant changeMaximum torque
Study
ratn: not reported in source
volumetric muscle loss
Comparator
Control (no IGF1-LR3)
Outcome group
Muscle injury and repair · Musculoskeletal
Studied dose
28 ug or 280 ug · implanted in hydrogel muscle void fillerAs given in this study (rat).
Source sentences
Summary
However, no differences were observed in specific torque or maximum torque production between any experimental groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult male Lewis rats underwent VML surgery, followed by implantation of a polyethylene glycol-acrylate MVF containing either soluble or poly(lactic-co-glycolic acid) (PLGA)-encapsulated IGF1-LR3 at a low (28 μg) or high (280 μg) dose, or no IGF1-LR3 (control).
Report a problemFND-4141866303
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with volumetric muscle loss, histology showed no change in muscle fibrosis with IGF1-LR3 compared with controls.
In plain wordsIn rats with muscle loss, IGF1-LR3 did not change scar-like tissue in muscle compared with control.
Peptide
IGF-1 LR3
Outcome
No significant changeMuscle fibrosis
Study
ratn: not reported in source
volumetric muscle loss
Comparator
Control (no IGF1-LR3)
Outcome group
Muscle injury and repair · Musculoskeletal
Studied dose
28 ug or 280 ug · implanted in hydrogel muscle void fillerAs given in this study (rat).
Source sentences
Summary
Histological analysis revealed no changes in muscle fibrosis or fiber size or count of IGF1-LR3 compared to controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult male Lewis rats underwent VML surgery, followed by implantation of a polyethylene glycol-acrylate MVF containing either soluble or poly(lactic-co-glycolic acid) (PLGA)-encapsulated IGF1-LR3 at a low (28 μg) or high (280 μg) dose, or no IGF1-LR3 (control).
Report a problemFND-4141866304
05AnimalAnimal study (in vivo)Efficacy outcome
In rats with volumetric muscle loss, histology showed no change in muscle fiber size with IGF1-LR3 compared with controls.
In plain wordsIn rats with muscle loss, IGF1-LR3 did not change muscle fiber size compared with control.
Peptide
IGF-1 LR3
Outcome
No significant changeMuscle fiber size
Study
ratn: not reported in source
volumetric muscle loss
Comparator
Control (no IGF1-LR3)
Outcome group
Muscle injury and repair · Musculoskeletal
Studied dose
28 ug or 280 ug · implanted in hydrogel muscle void fillerAs given in this study (rat).
Source sentences
Summary
Histological analysis revealed no changes in muscle fibrosis or fiber size or count of IGF1-LR3 compared to controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult male Lewis rats underwent VML surgery, followed by implantation of a polyethylene glycol-acrylate MVF containing either soluble or poly(lactic-co-glycolic acid) (PLGA)-encapsulated IGF1-LR3 at a low (28 μg) or high (280 μg) dose, or no IGF1-LR3 (control).
Report a problemFND-4141866305
06AnimalAnimal study (in vivo)Efficacy outcome
In rats with volumetric muscle loss, histology showed no change in muscle fiber count with IGF1-LR3 compared with controls.
In plain wordsIn rats with muscle loss, IGF1-LR3 did not change the number of muscle fibers compared with control.
Peptide
IGF-1 LR3
Outcome
No significant changeMuscle fiber count
Study
ratn: not reported in source
volumetric muscle loss
Comparator
Control (no IGF1-LR3)
Outcome group
Muscle injury and repair · Musculoskeletal
Studied dose
28 ug or 280 ug · implanted in hydrogel muscle void fillerAs given in this study (rat).
Source sentences
Summary
Histological analysis revealed no changes in muscle fibrosis or fiber size or count of IGF1-LR3 compared to controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult male Lewis rats underwent VML surgery, followed by implantation of a polyethylene glycol-acrylate MVF containing either soluble or poly(lactic-co-glycolic acid) (PLGA)-encapsulated IGF1-LR3 at a low (28 μg) or high (280 μg) dose, or no IGF1-LR3 (control).
Report a problemFND-4141866306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.